Bluejay Diagnostics (NASDAQ:BJDX) Major Shareholder Acquires $96,710.97 in Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) major shareholder Financial Lp Hrt acquired 64,047 shares of Bluejay Diagnostics stock in a transaction dated Thursday, July 9th. The shares were acquired at an average cost of $1.51 per share, with a total value of $96,710.97. Following the completion of the acquisition, the insider directly owned 126,993 shares in the company, valued at $191,759.43. This trade represents a 101.75% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Friday, July 10th, Financial Lp Hrt sold 34,938 shares of Bluejay Diagnostics stock. The shares were sold at an average price of $1.40, for a total transaction of $48,913.20.

Bluejay Diagnostics Stock Up 8.0%

NASDAQ BJDX opened at $1.35 on Thursday. Bluejay Diagnostics, Inc. has a twelve month low of $1.03 and a twelve month high of $16.68. The stock has a market cap of $1.39 million, a P/E ratio of -0.12 and a beta of 0.88. The company’s 50-day simple moving average is $2.66 and its 200 day simple moving average is $2.46.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics at the end of the most recent reporting period. 18.47% of the stock is currently owned by institutional investors.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.